Form PTO-1449 U.S. Departmen			nt of Commerce		Application Number	09/534,711					
Orm P10-1449 Patent and T			d Tra	demark Office		Filing Date	March 24, 2000				
	IP	1 atcht an				First Named Inventor	Philip Livingston				
10		RMATION DISCLOSUR	T ST			Art Unit	1642				
[Der	INFC	RMATION DISCLOSUR	•	Examiner Name	C. Yaen						
	1 7 20	se several sheets if n	ecessa	ı y <i>)</i>		Attorney Docket No.	1747/53437-A-PC	CT-			
图							US/JPW/CY				
Contract of the second		<u>**</u>	I C DA	TENT DOC	IIMENT	<u> </u>					
U.S. PATENT DOCUMENTS Date Name of Patentee or Applicant of Cited Document											
Examiner	miner Cite Document Number			Date DD-YYYY	Nam	e of Patentee of Applicat	If of Cited Documen				
Initials	No.1	Number-Kind Code						i			
<u> </u>			_								
	-						•				
	 		 								
	L										
			ļ								
					l						
	-										
	├ ──		 								
	<u> </u>		 		 						
			1		·						
	┼					_					
	-		 								
			 		 						
			ļ								
							·				
	1				[
	╁		 								
			ــــــــــــــــــــــــــــــــــــــ		ـــــ						
		· FO	DEICN	I PATENT I	OCUMI	ENTS					
	т —					Name of Patentee or A	pplicant of Cited	T ⁶			
Examiner	Cite	Foreign Patent Document Country Code ³⁻ Number ⁴⁻ Kind Code ^{5 (if known)}		Publication Date MM-DD-YYYY		Documen	nt				
Initials	110.										
CY	1	WO 94/16731 A1		08-04-1	994						
	† <u> </u>										
 	+					•					
<u> </u>	+			 				·			
	 							 			
L	 			·	+			 			
		L						Ш.—			
EXAMINE		Lhurs HX		DATE CONSI	DERED	3/30/05					
SIGNATU		in the interest of the state of the	ot citation	is in conforms	nce with M	PFP 609: Draw line through o	itation if not in conform	ance			
1		v t t		tion to annlican	t 'Anniicai	ar e unique citation designació	n numner tobuoliai). Se	E MIIIUS			
and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ² See Kinds and considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ² See Kinds of Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kinds are considered. The communication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kinds are considered.											
ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Name of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if											
English Language Translation is attached.											

Applicants: Philip O. Livingston, et al. Serial No.: 09/534,711 Filed: March 24, 2000 Exhibit A

Form <u>PTO</u>-1449

U.S. Department of Commerce Patent and Trademark Office

MATION DISCLOSURE CITATION (Use several sheets if necessary)

	Page 2 of 2
Application Number	09/534,711
Filing Date	March 24, 2000
First Named Invento	Philip Livingston
Art Unit	1642
Examiner Name	C. Yaen
Attorney Docket No.	: 1747/53437-A-PCT- US/JPW/CY

	NON PATENT LITERATURE DOCUMENTS			
	Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
_			IENNEMANN, R., et al., "Effects of Monophosphoryllipid-A on the Immunization of	
t [*]		2	Mice with Keyhole Limpet Hemocyanin- and Muramyldipeptide-ganglioside Gfptl Conjugates," J. Biochem., 119(2):378-384, (1996);	
d	cy	3	KIM, S. K., et al., "Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates", Vaccine, 19:530-537 (2001);	
	CY	4	LIVINGSTON, P.O., "Approaches to Augmenting the Immunogenicity Of Melanoma Gangliosides: From Whole Melanoma Cells to Ganglioside-KLH Conjugate Vaccines," Immunological Reviews, 145:147-166 (1995); and	
	сү	5	RAGUPATHI, G., et al., "Induction Of Antibodies Against GD3 Ganglioside In Melanoma Patients By Vaccination With GD3-Lactone-KLH Conjugate Plus Immunological Adjuvant QS-21", Int. J. Cancer, 85:659-666 (2000).	

EXAMINER DATE CONSIDERED 30/05

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English languale Translation is attached.